Cerulean Pharma Inc. (CERU) 5.99 $CERU Cerulean

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cerulean Pharma Inc. (CERU) 5.99 $CERU

Cerulean Announces Three Posters to be Presented with Preclinical CRLX101 Data at the American Association for Cancer Research Annual Meeting
Business Wire - Thu Apr 16, 6:02AM CDT
--CRLX101 monotherapy and in combination with Avastin shrinks tumors and prevents new metastases
CERU: 5.99 (-0.20)

Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells and Impedes Resistance to Anti-angiogenic Therapy in Preclinical Models
Business Wire - Mon Apr 13, 6:22AM CDT
Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting(TM), today announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Cerulean's lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models.
CERU: 5.99 (-0.20)

Cerulean concludes public offering of 6.716m common stock
M2 - Mon Apr 13, 5:34AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Friday that it has completed its public offering of 6,716,000 shares of common stock at a public offering price of USD6.00 per share.
CERU: 5.99 (-0.20)

InsiderInsights.com Daily Round Up 4/9/15: OVAS, AGCO, OPK, OGES
InsiderInsights - at Seeking Alpha - Fri Apr 10, 8:58AM CDT

ASH: 127.06 (+0.15), STFC: 23.83 (-0.01), MNST: 139.91 (+0.06), OVAS: 29.85 (-0.24), CERU: 5.99 (-0.20), AGCO: 48.16 (-0.16), GIII: 116.32 (-1.15), ASTI: 1.07 (+0.04), PANW: 153.87 (-0.50), TNET: 35.45 (-0.54), DRI: 65.20 (-0.09), FMI: 48.71 (-0.96), LNKD: 259.35 (+0.93), OPK: 14.60 (+0.17), DWRE: 65.40 (+1.36), RAVN: 20.69 (-0.04), TWTR: 51.73 (+0.41)

Cerulean Closes Public Offering of Common Stock
Business Wire - Fri Apr 10, 8:31AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the closing of its underwritten public offering of 6,716,000 shares of common stock, including 876,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $6.00 per share. The gross proceeds to Cerulean from this offering were approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Cerulean.
CERU: 5.99 (-0.20)

Cerulean to Present at 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:02AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15th at 5:00 p.m. ET in New York.
CERU: 5.99 (-0.20)

Nasdaq stocks posting largest volume increases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
JASN: 7.48 (-0.14), INFA: 47.92 (-0.03), TFSC: 9.70 (+0.09), QURE: 26.15 (-1.44), CERU: 5.99 (-0.20), SYRX: 2.09 (-0.05), NECB: 7.78 (-0.02), ESMC: 1.36 (-0.01), VLTC: 15.14 (-1.04), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), OCUL: 25.90 (-0.05)

Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 07, 5:15PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
VBFC: 19.86 (-0.12), IIIN: 21.41 (+0.20), CERU: 5.99 (-0.20), RCPT: 166.76 (-3.37), MGPI: 14.45 (+0.16), SCC.TO: 9.51 (-0.43), CBMG: 32.14 (+2.21), HCBK: 9.45 (+0.08), DGLY: 13.13 (+0.08), SRSC: 7.81 (-0.15), OCUL: 25.90 (-0.05), IKNX: 14.75 (-0.11)

Cerulean prices public offering at USD6.00 per share
M2 - Tue Apr 07, 6:57AM CDT
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Tuesday that it has priced a public offering of 5,840,000 shares of its common stock.
CERU: 5.99 (-0.20)

Cerulean prices equity offering
Seeking Alpha - at Seeking Alpha - Tue Apr 07, 5:58AM CDT

CERU: 5.99 (-0.20)

Cerulean Announces Pricing of Public Offering of Common Stock
Business Wire - Tue Apr 07, 5:03AM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced the pricing of an underwritten public offering of 5,840,000 shares of its common stock at a public offering price of $6.00 per share, before underwriting discounts. All of the shares in the offering are being offered by Cerulean. In addition, Cerulean has granted the underwriters an option for a period of 30 days to purchase up to 876,000 additional shares of common stock at the public offering price, less underwriting discounts.
CERU: 5.99 (-0.20)

Cerulean: Recently Announced Secondary Provides Interesting Opportunity
Chris Bunge - at Seeking Alpha - Mon Apr 06, 8:38PM CDT

CERU: 5.99 (-0.20)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT

KMX: 70.84 (-0.04), CARB: 11.14 (-0.07), TXMD: 7.17 (+0.01), CERU: 5.99 (-0.20), CNAT: 6.31 (-0.15), RPRX: 8.36 (-0.15), LBIO: 12.50 (+0.50), FXCM: 2.13 (+0.02), CAPN: 6.99 (-0.29), WBAI: 16.75 (-0.46)

Cerulean initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:32PM CDT

CERU: 5.99 (-0.20)

Cerulean Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 30, 3:20PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU) today announced that it has commenced an underwritten public offering of approximately $50 million of shares of its common stock. The number of shares to be offered and the price per share for the proposed offering have not yet been determined. All of the shares in the offering are to be sold by Cerulean.
CERU: 5.99 (-0.20)

Cerulean Pharma (CERU) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 6:42AM CDT
Cerulean Pharma (CERU) Shares March Higher, Can It Continue?
CERU: 5.99 (-0.20)

New chief at Cerulean Pharma
Seeking Alpha - at Seeking Alpha - Sat Mar 21, 11:30AM CDT

CERU: 5.99 (-0.20)

Cerulean Appoints Chris Guiffre President & Chief Executive Officer
Business Wire - Fri Mar 20, 3:41PM CDT
Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting(TM), today announced that Christopher D. T. Guiffre, J.D., M.B.A., has been appointed President & Chief Executive Officer.
CERU: 5.99 (-0.20)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Brixton Metals Delivers Promising Drill Results in Thorn Project

Updated Category News Views 167

Brixton Metals' Latest Drill Results Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) recently unveiled its second batch of drill results from the 2025 exploration season. The company operates the Thorn Project, an underexplored district known for its potential in copper-gold porphyry deposits. Highlighting Impressive Assay Results The recent drilling at the...

Continue Reading
US Labor Market Stagnation: A Closer Look at 2025 Trends

Updated Category News Views 275

November Layoffs and Hiring Trends In November, layoffs by U.S. employers reduced significantly, signaling a shift in the job market dynamics. Yet, companies are still hesitant to recruit new employees, indicating a labor market that remains restrained due to various pressures. Businesses are facing challenges such as soft demand, tariff implications, and soaring...

Continue Reading
Dollar Steady Amid Global Market Uncertainty and Yuan Weakness

Updated Category News Views 127

Asian Currency Markets React to U.S. Dollar Strength In the bustling arena of Asian currencies, the atmosphere is charged with anticipation as investors monitor the situation in China regarding potential economic stimulus measures. Meanwhile, the U.S. dollar is exhibiting remarkable strength, currently hovering near a two-and-a-half month high. This rise comes in light of...

Continue Reading
Understanding Recent Insider Trades at Omega Healthcare Invts

Updated Category News Views 75

Examining Insider Trades at Omega Healthcare Invts Recently, a notable insider trade involving Omega Healthcare Invts has drawn attention. Chief Operating Officer Daniel Booth executed a significant transaction, selling 56,725 shares as disclosed through an SEC filing. This particular sale took place on a recent date and revealed a total transaction value of $2,283,181....

Continue Reading
Exploring Future Growth in Healthcare Digital Payments Market

Updated Category News Views 150

Introduction to Digital Payments in Healthcare The transformation in the realm of healthcare is not just about treatments and services; it extends deeply into how payments are managed. The Digital Payment in Healthcare Market is evolving, with an anticipated growth in value reaching USD 61,521.8 Million by the year 2033. This incredible increase is projected to occur at a...

Continue Reading